Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
British Journal of Haematology|May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapyGordon Cook, A John Ashcroft, Guy Pratt, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 6, 2008
The synthesis and one- and two-photon optical properties of dipolar, quadrupolar and octupolar donor-acceptor molecules containing dimesitylboryl groupsJonathan C Collings, Suk-Yue Poon, Céline Le Droumaguet, et al.
The Lancet. Haematology|November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort studyJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Journal of Clinical Pharmacology|November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma PatientsMan Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Annals of Hematology|July 3, 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Blood Cancer Journal|August 12, 2024
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myelomaRajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Annals of Hematology|October 27, 2020
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapyGordon Cook, A John Ashcroft, Guy Pratt, et al.
Blood Advances|May 21, 2020
Search for multiple myeloma risk factors using Mendelian randomizationMolly Went, Alex J Cornish, Philip J Law, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 6, 2008
The synthesis and one- and two-photon optical properties of dipolar, quadrupolar and octupolar donor-acceptor molecules containing dimesitylboryl groupsJonathan C Collings, Suk-Yue Poon, Céline Le Droumaguet, et al.
The Lancet. Haematology|November 18, 2017
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort studyJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
Journal of Clinical Pharmacology|November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma PatientsMan Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Annals of Hematology|July 3, 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Blood Cancer Journal|August 12, 2024
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myelomaRajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Annals of Hematology|October 27, 2020
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaMartin Kaiser, Meral Beksaç, Nina Gulbrandsen, et al.
Pageof 16